First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma ..read more

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies ..read more

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma ..read more

Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels ..read more

Survival Advantage Demonstrated With Higher-Dose Rhenium-186 Nanoliposome in Recurrent Glioma The FDA has followed the recommendation of its Oncologic Drugs Advisory Committee and issued a complete response letter denying approval to 131I-omburtamab as a treatment for central nervous system and leptomeningeal metastases stemming from neuroblastoma. Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma. FDA Gives Priority Review to Tovorafenib ..read more

Treatment Algorithms with the Oncology Brothers ..read more

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032 ..read more

The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma ..read more

The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma ..read more

MDNA55 appears tolerable and effective in a cohort of patients enrolled in a phase 2b trial, showing sustained efficacy in subgroup analyses ..read more